Strategies for heating up cold tumors to boost immunotherapies
Immune checkpoint inhibitors induce significant and durable treatment responses in about
20% of all cancers, but many patients have natural resistance to current immunotherapies …
20% of all cancers, but many patients have natural resistance to current immunotherapies …
Advances in the lung cancer immunotherapy approaches
H Padinharayil, RR Alappat, LM Joy, KV Anilkumar… - Vaccines, 2022 - mdpi.com
Despite the progress in the comprehension of LC progression, risk, immunologic control,
and treatment choices, it is still the primary cause of cancer-related death. LC cells possess …
and treatment choices, it is still the primary cause of cancer-related death. LC cells possess …
[HTML][HTML] Effect of bone metastasis cancer board on spinal surgery outcomes: a retrospective study
K Miyazaki, Y Kanda, Y Sakai, R Yoshikawa, T Yurube… - Medicina, 2023 - mdpi.com
Background and Objectives: Bone metastasis cancer boards (BMCBs) focusing on the
management of bone metastases have been gathering much attention. However, the …
management of bone metastases have been gathering much attention. However, the …
Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens
Purpose To evaluate a new class of blood-based biomarkers, anti-frameshift peptide
antibodies, for predicting both tumor responses and adverse immune events to immune …
antibodies, for predicting both tumor responses and adverse immune events to immune …
The Importance of the Immune System and Molecular Cell Signaling Pathways in the Pathogenesis and Progression of Lung Cancer
J Smok-Kalwat, P Mertowska, S Mertowski… - International Journal of …, 2023 - mdpi.com
Lung cancer is a disease that in recent years has become one of the greatest threats to
modern society. Every year there are more and more new cases and the percentage of …
modern society. Every year there are more and more new cases and the percentage of …
Association between sex and outcomes in patients with non-small-cell lung cancer receiving combination chemoimmunotherapy as a first-line therapy: a systematic …
K Takada, M Shimokawa, F Mizuki, S Takamori… - European journal of …, 2022 - Springer
Introduction Recently, several meta-analyses have investigated the association between sex
and the efficacy of immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer …
and the efficacy of immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer …
[HTML][HTML] Challenges and knowledge gaps with immune checkpoint inhibitors monotherapy in the management of patients with non-small-cell lung cancer: a survey of …
L Castelo-Branco, G Morgan, A Prelaj, M Scheffler… - ESMO open, 2023 - Elsevier
Background Immune checkpoint-inhibitors (ICIs) are changing outcomes in different cancer
settings, notably for patients with non-small-cell lung cancer (NSCLC). There are, however …
settings, notably for patients with non-small-cell lung cancer (NSCLC). There are, however …
Identification of natural compounds tubercidin and lycorine HCl against small‐cell lung cancer and BCAT1 as a therapeutic target
Although small‐cell lung cancer (SCLC) accounts for a small fraction of lung cancer cases (~
15%), the prognosis of patients with SCLC is poor with an average overall survival period of …
15%), the prognosis of patients with SCLC is poor with an average overall survival period of …
Blood exosome PD-L1 is associated with PD-L1 expression measured by immunohistochemistry, and lymph node metastasis in lung cancer
Z Zhang, W **, K Xu, X Zheng, Y Zhou, M Luo, C Yan… - Tissue and Cell, 2022 - Elsevier
Background Previous observations illustrated that programmed cell death ligand 1 in
exosomes (Exo-PD-L1) may lead to immunosuppression. This study proposed to investigate …
exosomes (Exo-PD-L1) may lead to immunosuppression. This study proposed to investigate …
[HTML][HTML] Relative Efficacies of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Treatment of Recurrent Non-Small …
N Motono, T Mizoguchi, M Ishikawa, S Iwai, Y Iijima… - Oncology, 2024 - karger.com
Introduction: The relative efficacies of epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs) and immune checkpoint inhibitors (ICIs) for the treatment of recurrent …
inhibitors (EGFR-TKIs) and immune checkpoint inhibitors (ICIs) for the treatment of recurrent …